Novavax Inc vs Waste Management, Inc. — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Waste Management, Inc. trades at $227.79 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 69.2× Novavax Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WM | |
|---|---|---|
Market Cap | $1.31B | $90.68B |
Sector | Health | Industrials |
52-Week High | $11.19 | $246.51 |
52-Week Low | $6.22 | $196.77 |
Enterprise Value | $889.30M | $113.47B |
Dividend Yield | — | 1.56% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
WM trades at $226.6, down 0.47% over 24 hours, with a bullish technical signal and support near $226. The stock shows strong profitability with a 40.6% gross margin and 11.12% net margin, though its P/E of 59.74 is elevated. Recent Q2 2026 earnings beat expectations at $2.02 per share, and analyst consensus is a buy with a $263.43 price target. Cash flow from operations grew to $6.04B in 2025, but net cash flow was negative $190M due to investments.
Outlook is positive with revenue growth and margin stability, but risks include high valuation and debt levels. The stock offers upside to the consensus target, supported by institutional confidence and consistent earnings beats, though investors should monitor volume trends and interest rate impacts on borrowing costs.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →